The 2020 San Antonio Breast Cancer Symposium (SABCS) was held from December 8 to December 12, 2020. During the virtual...
Dr. William Flood, Chief Medical Officer for Eviti at NantHealth, discusses new significant findings from Eviti Connect, presented at the...
Here are the top 5 biosimilar articles for the week of December 14, 2020.
Investigators studying trastuzumab biosimilar savings and use rates across different disease settings in human epidermal growth factor receptor 2 (HER2)-positive...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to...
Topics to include DNA and RNA profiling and next-generation sequencing of tumors San Antonio, TX – Dec 3, 2018 –...